miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1
Author:
Publisher
Elsevier BV
Subject
Pharmacology,General Medicine
Reference45 articles.
1. Updates in non-small cell lung cancer;Walker;Clin. J. Oncol. Nurs.,2008
2. 2nd ESMO consensus Conference in lung cancer: locally advanced stage III non-small-cell lung cancer;Eberhardt;Ann. Oncol.,2015
3. Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer;Rose;Genomics Proteomics Bioinf.,2014
4. DNA repair and cisplatin resistance in non-small-cell lung cancer;Rosell;Lung Cancer,2002
5. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review);Wang;Oncol. Rep.,2004
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. KINETOCHORE SCAFFOLD 1 DOWNREGULATION SUPPRESSED THE DEVELOPMENT OF NON-SMALL CELL LUNG CANCER BY INACTIVATING THE PHOSPHATIDYLINOSITOL 3 KINASE/PROTEIN KINASE B (AKT)/NUCLEAR FACTOR-KAPPA B PATHWAY;J PHYSIOL PHARMACOL;2024
2. Emerging role of competing endogenous RNA in lung cancer drug resistance;Journal of Chemotherapy;2023-12-20
3. Design and synthesis of doublecortin-like kinase 1 inhibitors and their bioactivity evaluation;Journal of Enzyme Inhibition and Medicinal Chemistry;2023-12-07
4. Regulation and therapeutic potentials of microRNAs to non-small cell lung cancer;Heliyon;2023-11
5. Retraction notice to “miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1” [Biomed. Pharmacother. 106 (2018) 1072–1081];Biomedicine & Pharmacotherapy;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3